ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more
ENTERA BIO IS-0000769 (5DT) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ENTERA BIO IS-0000769 - Net Assets Trend (None–None)
This chart illustrates how ENTERA BIO IS-0000769's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ENTERA BIO IS-0000769 (None–None)
The table below shows the annual net assets of ENTERA BIO IS-0000769 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ENTERA BIO IS-0000769's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ENTERA BIO IS-0000769 Competitors by Market Cap
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OPTOMED OY A EO 005
F:36U0
|
$36.21 Million |
|
FCN Banc Corp
PINK:FBVI
|
$36.21 Million |
|
Neometals Ltd
OTCQX:NMTAY
|
$36.21 Million |
|
PLANETREE INTL.DEV.HD-10
F:YUIA
|
$36.22 Million |
|
Jinhui Shipping and Transportation Limited
PINK:JNSTF
|
$36.20 Million |
|
EdiliziAcrobatica S.p.A
PA:ALEAC
|
$36.20 Million |
|
Train Alliance Sweden AB (publ)
F:7EF
|
$36.20 Million |
|
Sturgis Bancorp Inc
OTCQX:STBI
|
$36.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENTERA BIO IS-0000769's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ENTERA BIO IS-0000769's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ENTERA BIO IS-0000769 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ENTERA BIO IS-0000769's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENTERA BIO IS-0000769 (5DT) | €- | N/A | N/A | $36.20 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |